Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
A considerable need exists for improved biomarkers for differential diagnosis, prognosis and monitoring of therapeutic interventions for mucopolysaccharidoses (MPS), inherited metabolic disorders that involve lysosomal storage of glycosaminoglycans. Here we report a simple, reliable method based on the detection of abundant nonreducing ends of the glycosaminoglycans that accumulate in cells, blood and urine of individuals with MPS. In this method, glycosaminoglycans are enzymatically depolymerized, releasing unique mono-, di- or trisaccharides from the nonreducing ends of the chains. The composition of the released mono- and oligosaccharides depends on the nature of the lysosomal enzyme deficiency, and therefore they serve as diagnostic biomarkers. Analysis by LC/MS allowed qualitative and quantitative assessment of the biomarkers in biological samples. We provide a simple conceptual scheme for diagnosing MPS in uncharacterized samples and a method to monitor efficacy of enzyme replacement therapy or other forms of treatment.
Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California San Diego, La Jolla, California, USA.
Roger
R
Lawrence
Jillian R
JR
Brown
Kanar
K
Al-Mafraji
William C
WC
Lamanna
James R
JR
Beitel
Geert-Jan
GJ
Boons
Jeffrey D
JD
Esko
Brett E
BE
Crawford
D015415:Biomarkers; D002241:Carbohydrates / Q000032:analysis*; D003937:Diagnosis, Differential; D006025:Glycosaminoglycans / Q000032:analysis* / Q000378:metabolism; D006801:Humans; D013058:Mass Spectrometry; D008722:Methods; D009083:Mucopolysaccharidoses / Q000175:diagnosis*; D009844:Oligosaccharides / Q000032:analysis; D011379:Prognosis
D015415:Biomarkers; D002241:Carbohydrates; D006025:Glycosaminoglycans; D009844:Oligosaccharides